Elk Creek Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Elk Creek Partners’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$7.44M	Buy	118,188 +27,384	+30%	+$2.46M	1.28%	24
2019 Q4	$11.3M	Sell	90,804 -70,602	-44%	-$6.32M	1.29%	21
2019 Q3	$10.7M	Buy	+161,406	New	+$10.8M	0.92%	43
2019 Q1	–	Sell	-207,657	Closed	-$20.9M	–	141
2018 Q4	$20.9M	Sell	207,657 -26,478	-11%	-$2.74M	1.74%	8
2018 Q3	$29.6M	Sell	234,135 -152,262	-39%	-$16.1M	1.6%	9
2018 Q2	$32.4M	Buy	386,397 +37,943	+11%	+$2.78M	1.78%	7
2018 Q1	$21.4M	Buy	+348,454	New	+$21M	1.25%	21

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Elk Creek Partners's ICPT Position: Q1 2020 in Review

Elk Creek Partners increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 30% in Q1 2020, buying an estimated $2.46M and bringing the position to 118,188 shares worth $7.44M. The position accounts for 1.28% of the portfolio, ranked #24.

Elk Creek Partners first reported a position in ICPT in Q1 2018 and has held it in 7 quarters since. The position peaked at $32.4M in Q2 2018. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

Elk Creek Partners held 118,188 shares of Intercept Pharmaceuticals, Inc. worth $7.44M as of Q1 2020.
Elk Creek Partners bought 27,384 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $2.46M.
Intercept Pharmaceuticals, Inc. made up 1.28% of Elk Creek Partners's portfolio in Q1 2020, its #24 holding.
Elk Creek Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2018 and has held it in 7 quarters since.
Elk Creek Partners's Intercept Pharmaceuticals, Inc. position peaked at $32.4M in Q2 2018.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.